


# KYT OPEN



*Healthy and functional cells from discovery to manufacturing*

June 2021

[hello@kytopen.com](mailto:hello@kytopen.com)

IMPACT

PASSION

INTEGRITY

RESILIENCE

INCLUSIVITY


# Promise...and Challenges of Cell Therapies



## Today's Approved Therapies

Autologous  
Viral  
Single gene modification  
Small payloads  
Expensive (\$0.5M-\$2M)  
Variable MFG

## Example of Cell Therapy Manufacturing



## Tomorrow's Approved Therapies

Autologous & Allogeneic  
Viral & Non-Viral  
Multiple gene edits  
Large payloads  
Cost-effective  
Consistent MFG

# Kytopen Enables Next-Gen Cell Therapies




**Kytopen delivers therapeutic solutions to the clinic faster,  
for the benefit of mankind.**

**“It’s the same.”**

***Flowfect® Array***

R&D  
(~100 µL)



***Flowfect® Tx***




Manufacturing  
(>10 mL)

Factor  
100x - 1,000x

Fully automated process


Throughput > 1 billion cells/min

# *Flowfect*<sup>®</sup> equivalent at small and large scale

KYTO<sup>®</sup>PEN

*Flowfect*<sup>®</sup> Array platform optimization parameters scale to the *Flowfect*<sup>®</sup> Tx platform with no difference observed in cell viability or delivery efficiency between the platforms (functionally equivalent <5% difference)

# Kytopen *Flowfect*<sup>®</sup> Delivery Progress



# Kytopen Management Team




**Paulo Garcia, Ph.D.**  
**CEO & Co-Founder**  
 Corporate Strategy,  
 BD & Partnerships,  
 Biomedical Engineer



**Cullen Buie, Ph.D.**  
**CTO & Co-Founder**  
 MIT Faculty (MechE),  
 Tech. Development, IP,  
 Collaborations



**Bethany Grant**  
**Head of R&D**  
 Aero/Mech Eng  
 Med Device Development  
 J&J, Atlantis (AZ acquired)



**Michael Elliott**  
**COO**  
 Global Operations  
 P&L Management  
 MBA/Mech Eng



**Greg Crescenzi**  
**Chief Commercial Officer**  
 Innovative Technologies  
 Prior: Cytiva/GE Healthcare,  
 BD, Pall, & Merck Millipore



**Theresa Tribble**  
**Board Member**  
 Operating Partner, The Engine  
 Prior: EverlyWell (CBO),  
 SynapDx (VP Commercial)

## Kytopen (MIT spinout)

### Financing

- \$9M in funds raised to date (dilutive + non-dilutive) secured
- \$2M NIH (NK cells) SBIR (Priority Score: 27) **Intent to Award**

### Intellectual Property

- 5 patents for *Flowfect*<sup>®</sup> apparatus, kits, and methods of use
- Exclusive license for MIT portfolio (2 patents USA & EU)
- Kytopen wholly-owned portfolio (3 pending-patents WW)

### Investors

- The Engine
- Horizons Ventures
- MassVentures
- Experienced Biotech Angels




**Breakthrough Bioinnovation**  
*Flowfect*<sup>™</sup> Tx Co-Development



**Cell & Gene Therapy Experts**  
 Regulatory Strategy

# KYT OPEN



*Healthy and functional cells from discovery to manufacturing*

June 2021

[hello@kytopen.com](mailto:hello@kytopen.com)

IMPACT

PASSION

INTEGRITY

RESILIENCE

INCLUSIVITY